In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...
In the case of LEAP, however, the state is doing both. The IEDC and Lebanon officials have collectively pledged nearly $1.8 ...
Lebanon Mayor Matthew Gentry in autumn struck a deal with Citizen’s Energy Group to bring 25 million gallons per day to ...
The project aims to attract more visitors to the Miller Woods, Paul H. Douglas Center for Environmental Education and Gary's Miller neighborhood on the west end of the park and the Mount Baldy Beach ...
Eli Lilly estimates that is about 15-20 million adults in the U.S. Obstructive sleep apnea isnt just an inconvenience, its a serious medical condition that impairs breathing and sleep quality.
Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli ... 1 drugs. Lilly’s Zepbound, approved in November 2023 as the Indiana ...
After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on ... health care researcher KFF. (Neither Indiana nor any of its neighbors offer such ...
This year's developments in the obesity market have really gone in Eli Lilly’s (NYSE:LLY) favor. Clinical trial results from competitors were largely underwhelming, including this week’s ...
Both the scholarship program and the LSN are supported by grants from Lilly Endowment to Independent Colleges of Indiana ... and his sons Eli and J.K. Jr. through gifts of stock in their ...
The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s Zepbound and Mounjaro has been resolved, eliminating the need for copycat versions of the drugs that have become ...
On Dec. 9, healthcare giant Eli Lilly announced the approval of a new $15 billion share buyback program and yet another significant dividend increase. For a seventh consecutive year, the company ...
Like Leqembi, Lilly's Kisunla is designed to clear an Alzheimer's-related protein called beta-amyloid from the brain. In a large, late-stage trial, Kisunla slowed the progression of memory and ...